In accordance with Ho et al., who implicated basal subtype cancers with poor clinical outcomes and better outcomes in intermediate subtype cancers, the high-grade metastatic human T24 showed a higher expression level of CD44 than the non-metastatic well differentiated RT122, respectively [44]. Here, CD44 is linked to cancer.